Peptide Therapy· 19 min read
Epitalon, Sleep, and the Aging Brain: What a Psychiatrist Wants You to Know
Update, July 24, 2026: The FDA’s Pharmacy Compounding Advisory Committee voted to recommend adding epitalon to the 503A compounding list, and the indication it voted on was insomnia. STAT News reported the tally as 7-4. RAPS Regulatory Focus counted it 7-5 with 1 abstention. The FDA’s own reviewers had recommended against it. They looked for human studies of epitalon in insomnia and found none, and the gap covers every kind of sleep measurement, including polysomnography, actigraphy, validated sleep questionnaires, sleep latency, and total sleep time. There are no animal sleep studies either. Reviewers also raised immunogenicity risk and concerns about peptide impurities. The committee went the other way. This is a recommendation, not an approval. Epitalon still isn’t FDA-approved, and the FDA would have to accept the recommendation and complete rulemaking, usually 12 to 24 months, before a compounding pharmacy could make it. FDA hasn’t posted the official meeting record yet, so the tallies come from reporters who were in the room.
Where I stand on offering it: I don’t prescribe epitalon today, and I can’t, because it isn’t eligible for compounding. If the FDA accepts the recommendation and finishes rulemaking, I’ll offer it to patients where the clinical picture supports it. The evidence below is what I’d be deciding from. When I do write for it, it comes with written consent that names the gaps and with cancer screening. That last condition isn’t hypothetical. The FDA’s reviewers wrote that by upregulating telomerase and extending telomeres past the point where cells escape senescence, epitalon “has the potential to be carcinogenic.” They tied that to chronic continuous exposure. Khavinson’s own group has hypothesized the opposite for intermittent courses, and the FDA didn’t adopt that view.
Semax went to the same committee on the same two days and got a favorable vote of its own, and it still cannot be compounded. I work through what that vote actually permits in is semax legal after the 2026 FDA vote.
Epitalon, Sleep, and the Aging Brain: What a Psychiatrist Wants You to Know
Most of what’s written about the epitalon peptide focuses on telomeres and longevity. The peptide’s ability to activate telomerase and potentially slow cellular aging has made it a favorite in biohacking and anti-aging circles. But the clinical relevance that gets overlooked is more immediate and more practical: epitalon’s effects on the pineal gland, melatonin production, and circadian rhythm.
Epitalon was one of the peptides the FDA reviewed for compounding in July 2026, and I weighed its evidence against the others in the peptide vote breakdown.
Epitalon went to the FDA’s compounding advisory committee for insomnia in July 2026. What that means for access is covered in my 2026 FDA peptide decision guide.
For a psychiatrist, that’s where the conversation starts. Sleep disruption, circadian dysfunction, and declining melatonin output are not just aging inconveniences. They’re drivers of depression, anxiety, cognitive decline, and treatment resistance. Understanding what epitalon does (and doesn’t do) at the intersection of sleep and psychiatric health is essential for anyone considering this peptide as part of a broader treatment plan.
What Is Epitalon
Epitalon (also spelled epithalon or epithalone) is a synthetic tetrapeptide consisting of four amino acids: alanine, glutamic acid, aspartic acid, and glycine (Ala-Glu-Asp-Gly). It was developed by Russian scientist Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, based on epithalamin, a peptide complex extracted from bovine pineal glands (1).
The pineal gland produces melatonin, the hormone that regulates sleep-wake cycles. As the pineal gland ages, melatonin production declines. This decline is associated with disrupted circadian rhythms, poor sleep quality, and a cascade of downstream effects on mood, cognition, immune function, and metabolic health (2).
Epitalon is proposed to support pineal gland function and restore endogenous melatonin production, rather than replacing melatonin from the outside. That distinction matters clinically: exogenous melatonin supplementation provides the hormone directly but can suppress the body’s own production over time. Epitalon, in theory, helps the pineal gland make its own melatonin in a physiologically appropriate circadian pattern (3).
The Melatonin Connection: Why Psychiatrists Care
Melatonin is not just a sleep hormone. It’s a neuromodulator with broad effects on psychiatric function.
Depression. Disrupted melatonin secretion is a consistent finding in major depressive disorder. The circadian rhythm flattening seen in depression (blunted cortisol curves, disrupted sleep architecture, altered temperature rhythms) is closely linked to declining pineal output. Agomelatine, an antidepressant that acts on melatonin receptors (MT1 and MT2), demonstrates that restoring melatonergic signaling can have direct antidepressant effects (4).
Anxiety. Melatonin modulates GABAergic signaling, which is the same system targeted by benzodiazepines. Declining melatonin may contribute to the increased baseline anxiety and reduced stress resilience seen in aging.
Cognitive decline. Melatonin is a potent antioxidant in the central nervous system. It protects against oxidative damage, reduces neuroinflammation, and supports hippocampal neuroplasticity. The correlation between declining melatonin and increased risk of neurodegenerative conditions is well documented (5).
HPA axis regulation. Melatonin and cortisol exist in an inverse relationship. When melatonin production declines with age, cortisol rhythms lose their normal circadian shape. Chronic cortisol dysregulation is a hallmark of both depression and anxiety disorders. Research in senescent monkeys demonstrated that epitalon significantly stimulated evening melatonin synthesis, which in turn normalized cortisol circadian rhythms (6).
Sleep also drives the overnight release of growth hormone and IGF-1, so the same circadian decline that lowers melatonin can blunt the body’s anabolic hormones in men.
That’s the psychiatric argument being made for epitalon. A disrupted circadian rhythm makes psychiatric conditions worse and psychiatric treatments less effective. Whether epitalon restores that rhythm in humans is the part nobody has measured.
Wondering where peptide therapy stands right now, and what it means for your psychiatric care? I’ll give you the current legal picture and look at what’s driving your sleep.
What the Research Shows
Telomerase activation and telomere elongation. Epitalon’s signature mechanism is its ability to activate telomerase, the enzyme that maintains telomere length. In 2003, Khavinson demonstrated that epitalon induced telomerase activity and telomere elongation in human fetal fibroblast cultures, extending their replicative lifespan beyond the Hayflick limit (7). A 2025 study confirmed these findings, showing dose-dependent telomere extension in both normal and cancer cell lines, with normal cells extending telomeres through telomerase upregulation specifically (8).
The psychiatric relevance of telomere biology is increasingly recognized. Shortened telomeres are associated with depression, PTSD, chronic stress, and accelerated biological aging. Whether maintaining telomere length through epitalon translates to clinical psychiatric benefit in humans remains unproven, but the theoretical framework connecting telomere health, cellular resilience, and psychiatric outcomes is growing (9).
Melatonin restoration in aging humans and primates. A study in elderly people found that epithalamin (the natural peptide complex that epitalon is based on) modulated pineal gland function: patients with low baseline melatonin showed increased nighttime melatonin levels after treatment, while those with normal function showed no overshoot (3). This modulating (rather than overriding) effect distinguishes epitalon from exogenous melatonin supplementation.
A primate study showed that epitalon significantly stimulated evening melatonin synthesis in senescent monkeys and normalized their cortisol circadian rhythm (6). The cortisol normalization is particularly relevant for psychiatry: HPA axis dysregulation is a core feature of depression, and restoring the cortisol curve through circadian correction is a recognized therapeutic target.
Antioxidant and neuroprotective effects. In aging rats, epitalon increased the activity of superoxide dismutase, glutathione peroxidase, and glutathione-S-transferase, all key antioxidant enzymes (10). Epithalamin was shown to protect hippocampal neurons from free-radical damage during acute hypoxia more effectively than exogenous melatonin alone (11). These neuroprotective effects are relevant to the neuroinflammatory model of depression, where oxidative stress and reduced antioxidant capacity contribute to neuronal damage and treatment resistance.
Immune modulation. Epitalon appears to increase lymphocyte proliferation in the thymus and enhance interferon gamma production. A prospective cohort study of 266 people over age 60 found that treatment with epithalamin produced a 1.6 to 1.8-fold reduction in mortality over six years (1). While these are longevity endpoints, the immune-psychiatric connection is relevant: neuroinflammation driven by immune dysregulation is increasingly implicated in treatment-resistant depression and cognitive decline.
Neurogenesis. A 2020 study demonstrated that epitalon stimulated gene expression and protein synthesis during neurogenesis through an epigenetic mechanism, suggesting that the peptide may support the brain’s capacity for neural repair and adaptation (12).
What the Research Does Not Show
Transparency about the limitations of epitalon research is essential. The evidence has significant gaps.
The vast majority of published studies come from the St. Petersburg Institute of Bioregulation and Gerontology, primarily under Vladimir Khavinson’s supervision. Independent Western replication is minimal. The 2025 telomere study from the UK represents the first significant independent confirmation of epitalon’s telomerase-activating effects (8), but the overall body of evidence remains concentrated in one research group.
No large-scale randomized controlled trials have evaluated epitalon for any psychiatric indication. The sleep benefits commonly reported by users have not been validated in controlled settings. The longevity claims are based on animal studies and small human cohorts. Long-term safety in humans is not established through rigorous clinical trials.
Epitalon isn’t FDA-approved. A bulk substance qualifies under section 503A by having a USP or NF monograph, by being a component of an approved drug, or by appearing at 21 CFR 216.23. Epitalon has none of the three. When the FDA looked, it couldn’t identify any pharmacy compounding epitalon in any form.
Epitalon vs. Melatonin Supplementation
This is the comparison patients most often ask about, and the distinction matters clinically.
Exogenous melatonin provides the hormone directly. It works quickly, it’s accessible, and it’s useful for acute sleep onset issues or jet lag. However, long-term exogenous melatonin use can suppress the pineal gland’s own production through negative feedback. It also doesn’t address the underlying age-related decline in pineal function. Dosing is often poorly calibrated: most over-the-counter melatonin supplements provide supraphysiologic doses (3 to 10 mg) that far exceed the body’s natural production (typically 0.1 to 0.3 mg).
Epitalon is proposed to restore the pineal gland’s ability to produce melatonin endogenously, in a circadian-appropriate pattern. The clinical data showing that epitalon increases melatonin only in individuals with low baseline levels (and does not cause overproduction in those with normal levels) suggests a modulating rather than overriding effect (3). This is a more physiologically compatible approach, though the evidence base is smaller and the peptide is less accessible.
For patients already on psychiatric medications that affect sleep (SSRIs, SNRIs, stimulants, atypical antipsychotics), the practical question is melatonin timing and dose against the rest of the regimen. A psychiatrist managing the overall treatment plan can evaluate how circadian interventions interact with existing medications.
Sleep problems making your psychiatric symptoms worse? I evaluate circadian, hormonal, and psychiatric factors together.
Who Might Benefit from Epitalon
No sleep trial has tested any of this. These are the clinical profiles where the mechanism would predict a benefit, and where I’d look first if epitalon became prescribable:
Adults over 40 with declining sleep quality. Age-related melatonin decline typically becomes clinically noticeable in the 40s and 50s. Sleep onset difficulty, fragmented sleep, reduced deep sleep, and early morning waking can all reflect declining pineal function.
Patients with treatment-resistant depression and circadian disruption. When depression doesn’t respond to standard antidepressant therapy, circadian rhythm dysfunction should be on the differential. The proposal is that restoring diminished melatonin would improve both sleep architecture and the downstream mood effects of sleep deprivation. The FDA’s reviewers questioned even that premise, citing evidence that low melatonin hasn’t been consistently linked to insomnia in older adults.
Patients on psychiatric medications that disrupt sleep. Stimulants for ADHD, activating antidepressants (bupropion, fluoxetine), and some atypical antipsychotics can all interfere with sleep. Adding circadian support before a sedating medication is a reasonable clinical consideration. Today that means light timing and sleep scheduling.
Patients interested in metabolic-psychiatric optimization. Patients already on peptide therapy or on FDA-approved GLP-1 medications for weight management and hormonal optimization often raise epitalon as an adjacent question. The circadian and neuroprotective claims sit right next to the metabolic ones.
Who should not use epitalon: patients with active cancer (telomerase activation is a theoretical concern in malignancies), pregnant or breastfeeding women, and anyone with a history of peptide hypersensitivity. If you’re taking a peptide, wherever you got it, you need a medical screening and a full clinical evaluation.
The Committee Backed It for Insomnia. Here’s What the Insomnia Evidence Actually Is.
Insomnia is the indication the advisory committee voted on, so it’s worth being precise about what sits behind it. The answer surprised me when I went through the FDA’s review.
There are no human studies of epitalon in insomnia. There aren’t small ones or weak ones either. The FDA’s reviewers searched and reported finding none, and the gap covers every kind of sleep measurement, including polysomnography, actigraphy, validated sleep questionnaires, sleep latency, and total sleep time. They also found no animal work on behavioral or EEG endpoints of sleep.
What does exist is a single study, and it’s worth walking through because it is carrying the entire indication. Ivko and colleagues randomized 40 healthy women aged 40 to 50 who worked night shifts to a sublingual peptide spray at 0.5 mg per day or saline placebo for 20 days. Urinary 6-sulfatoxymelatonin, a melatonin metabolite, rose about 1.7-fold. Two circadian genes normalized. The authors also reported positive changes in “psycho-emotional and general physical condition” in 83% of the treated group against 25% on placebo.
Three problems come up if you want to read that as an insomnia trial. The publication didn’t specify blinding. The authors gave no detail on how they assessed that psycho-emotional measure, which the FDA reviewers flagged directly. And the study measured no sleep outcome at all. Its subjects were healthy night-shift workers rather than people with insomnia, and it used a sublingual spray, while the product sold today is a subcutaneous injection.
A melatonin metabolite moved in a urine sample. That is the whole case. The FDA’s reviewers went a step further and questioned the premise underneath it, citing evidence that low melatonin levels haven’t been consistently associated with insomnia in older adults in the first place.
The honest summary is that nobody has measured whether epitalon helps people sleep. That leaves the question open rather than settled, and it’s the reason I’d want a trial before telling a patient this works.
Frequently Asked Questions
Is epitalon FDA-approved?
No, and it isn’t approved anywhere the FDA could verify. Its reviewers found no approved epitalon products in Canada, Australia, the UK, Belgium, Ireland, France, Norway, Germany, Spain, or Italy, and none authorized by the European Medicines Agency. It did receive US orphan drug designation for retinitis pigmentosa in September 2010, which the FDA revoked in January 2016. On July 24, 2026, an FDA advisory committee voted to recommend adding it to the 503A compounding list for insomnia, reported as 7-4 by STAT News and as 7-5 with 1 abstention by RAPS Regulatory Focus. That’s a recommendation, not an approval, and rulemaking would still run 12 to 24 months. Most of the clinical research has been conducted in Russia, with independent Western studies beginning to emerge.
How is epitalon administered?
Epitalon is typically administered via subcutaneous injection. Common protocols involve daily injections for 10 to 20 days, repeated two to three times per year. Worth knowing that no human pharmacokinetic study of epitalon exists, so there’s no established dose, no known half-life, and no target blood level. Those protocols come from practice convention rather than dose-finding studies. Every protocol circulating online traces back to a research setting or a grey-market vendor.
Can epitalon help with insomnia?
Nobody knows, because nobody has measured it. The FDA’s reviewers searched for human studies of epitalon in insomnia and found none, along with no sleep outcomes of any kind and no animal sleep studies. The mechanism people cite, restoring an age-related decline in melatonin, rests on studies that measured melatonin metabolites rather than sleep, and the FDA noted that low melatonin hasn’t been consistently linked to insomnia in older adults anyway. People do report better sleep on it. Those reports are uncontrolled, unblinded, and collected from people who paid for the product. I’d want a trial before telling a patient it works.
Is epitalon safe to use with psychiatric medications?
There are no known direct drug interactions between epitalon and standard psychiatric medications (SSRIs, SNRIs, mood stabilizers, stimulants, benzodiazepines). However, any peptide that affects melatonin production could theoretically interact with medications that influence circadian rhythm or sleep architecture. If you’re taking epitalon you bought online, the clinician managing your psychiatric medications needs to know about it.
How does epitalon compare to other sleep peptides like DSIP or Selank?
Each targets a different mechanism. DSIP (delta sleep-inducing peptide) is marketed for slow-wave sleep; the human evidence is limited and unconfirmed, which I cover in my guide to the DSIP peptide. Selank is proposed to work on anxiety-driven insomnia through GABAergic and serotonergic modulation. Epitalon works further upstream, on the age-related decline in melatonin production. Both cases rest on mechanism, and no sleep trial has tested either one. If anxiety is driving the insomnia, selank is the more sensible target. If the problem is difficulty falling asleep at the right time, early morning waking, or fragmented sleep from declining melatonin, epitalon is. None of the peptides on this page can be legally compounded in the US today.
Does epitalon cause cancer?
The question is unresolved, and the data point in both directions. In lifetime mouse studies epitalon reduced spontaneous tumors and metastases (1). The FDA’s reviewers reached a different conclusion about chronic human use, writing that by upregulating telomerase and extending telomeres past the point where cells escape senescence, epitalon “has the potential to be carcinogenic.” The 2025 UK study found it lengthened telomeres in normal cells through telomerase and in breast cancer cells through a separate mechanism (8). One detail rarely reported: the reassuring mouse data came from roughly 3 to 40 micrograms per kilogram given five days a month, while clinics sell 5 to 10 milligrams daily on a continuous schedule. Those exposures differ by about four orders of magnitude. Anyone with an active malignancy, a cancer predisposition, or an undiagnosed mass should treat this as a reason for caution.
Is epitalon legal in 2026?
It isn’t a controlled substance, and it isn’t an approved drug. In April 2026 epitalon came off category 2 of the FDA’s interim compounding policies, after both of its nominators withdrew their nominations. It still appears on the FDA’s list of substances that may present significant safety risks. It’s filed there under substances that were nominated and then withdrawn. That heading carries no compounding eligibility. The July 24 advisory vote recommended moving it onto the 503A list. Until the FDA accepts that recommendation and completes rulemaking, the legal status hasn’t changed. What’s sold online as “research grade” sits outside that system entirely.
Can I get epitalon from a compounding pharmacy right now?
No. When the FDA looked, it could not identify any pharmacy compounding epitalon in any form, and one pharmacy owner who compounded and distributed epitalon-containing products pleaded guilty to unlawful distribution. Anything sold as compounded epitalon today deserves hard questions about where it came from.
Already taking a peptide for sleep alongside your psychiatric medications? Have the vial and the label with you at the visit and we’ll look at the whole picture.
How Dr. Baghel Approaches Epitalon
I’m a board-certified psychiatrist (ABPN), and I work with 503A compounding pharmacies. I’d prescribe epitalon if I could. When a patient asks, I look at it against their psychiatric medications, their hormones, and the rest of their treatment plan.
For patients considering epitalon, the evaluation begins with a psychiatric assessment and a review of sleep patterns, circadian function, current medications, and metabolic health. Psychiatric illness, hormonal changes, medication side effects, and age-related pineal decline all produce the same sleep complaint. Separating them changes what I treat.
I see patients by video anywhere in North Carolina, and in person at my Wilmington office by request. Pricing is $250/month flat and covers up to four visits a month for psychiatric and hormonal care. Labs and medications are paid separately by the patient.
Sleep, Mood, and Aging Are Connected. Your Treatment Plan Should Be Too.
I manage psychiatric medications and hormonal therapy under one plan for patients across North Carolina, and I’ll add peptide therapy if it becomes legally available.
Baghel Psychiatry, PLLC | Shantanu Baghel, DO | (910) 612-6015 | sbaghel@thebh.us
This article is for educational purposes only and does not constitute medical advice. Epitalon is not FDA-approved for any indication. Patients should not start, stop, or change medications without consulting a qualified healthcare provider. Peptide therapy availability depends on current compounding pharmacy regulations. Epitalon can’t be legally compounded in the United States as of August 2026. Monthly plan covers Dr. Baghel’s clinical services only (evaluation, monitoring, medication management, ongoing care). Labs and medications are not included and are paid separately by the patient.
References
1. Khavinson VK. Peptides and ageing. Neuroendocrinology Letters. 2002;23(Suppl 3):11-144. PMID: 12374906
2. Khavinson VK, Linkova NS. Morphofunctional and molecular bases of pineal gland aging. Human Physiology. 2012;38(1):101-107. doi:10.1134/S0362119712010112
3. Korkushko OV, Khavinson VK, Shatilo VB, Magdich LV. Effect of peptide preparation epithalamin on circadian rhythm of epiphyseal melatonin-producing function in elderly people. Bulletin of Experimental Biology and Medicine. 2004;137(4):389-391. PMID: 15452611
4. De Berardis D, Orsolini L, Serroni N, et al. The role of melatonin and agomelatine in the treatment of anxiety disorders. Current Pharmaceutical Design. 2016;22(24):3661-3669.
5. Reiter RJ, Tan DX, Galano A. Melatonin: exceeding expectations. Physiology. 2014;29(5):325-333.
6. Khavinson V, Goncharova N, Lapin B. Synthetic tetrapeptide epitalon restores disturbed neuroendocrine regulation in senescent monkeys. Neuroendocrinology Letters. 2001;22(4):251-254. PMID: 11524632
7. Khavinson VK, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine. 2003;135(6):590-592. PMID: 12937682
8. Al-Dulaimi S, Thomas R, Matta S, Roberts T. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025;26(5):178. PMID: 40908429. Erratum in Biogerontology. 2025;27(1):1.
9. Simon NM, Smoller JW, McNamara KL, et al. Telomere shortening and mood disorders: preliminary support for a chronic stress model of accelerated aging. Biological Psychiatry. 2006;60(5):432-435.
10. Khavinson VK, Bondarev IE, Butyugov AA, Smirnova TD. Peptide promotes overcoming of the division limit in human somatic cell. Bulletin of Experimental Biology and Medicine. 2004;137(5):503-506.
11. Sopova IY. Effects of melatonin and epithalamin on the content of protein and lipid peroxidation products in the cortex and hippocampus of hypoxic rats. Neuroscience and Behavioral Physiology. 2006.
12. Khavinson V, Diomede F, Mironova E, et al. AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism. Molecules. 2020;25(3):609. PMID: 32019204
Related Articles
Semax and Selank for Anxiety, Depression, PTSD, and Cognition
BPC-157: What It Is, How It Works, and What the Research Actually Shows
Peptides vs SSRIs for Depression and Anxiety
GLP-1 Medications and Mental Health: What Your Psychiatrist Wants You to Know